Marilyn M. Schapira

Marilyn M. Schapira

Auto-generated profile, based on publicly available information

Marilyn M. Schapira

Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2018 in Journal of Medical Internet Research
Verified
Journal Article
Open access
CPCharles A Phillips
Charles A Phillips
ALAllison Barz Leahy
Allison Barz Leahy
YLYimei Li
Yimei Li
MSMarilyn M. Schapira
Marilyn M. Schapira
LBL. Charles Bailey
L. Charles Bailey
RMRaina M. Merchant
Raina M. Merchant
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

1 August 2023 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
MSMarilyn M. Schapira
Marilyn M. Schapira
RHRebecca A. Hubbard
Rebecca A. Hubbard
JWJeff Whittle
Jeff Whittle
AVAnil Vachani
Anil Vachani
DKDana Kaminstein
Dana Kaminstein
LFLiana Fraenkel
Liana Fraenkel
Importance: Guidelines recommend shared decision-making prior to initiating lung cancer screening (LCS). However, evidence is lacking on how to best implement shared decision-making in clinical practice.Objective: To evaluate the impact of an LCS Decision Tool (LCSDecTool) on the quality of decision-making and LCS uptake.Design, Setting, and Participants: This randomized clinical trial enrolled participants at Veteran Affairs Medical Centers in Philadelphia, Pennsylvania; Milwaukee, Wisconsin; and West Haven, Connecticut, from March 18, 2019, to September 29, 2021, with follow-up through July 18, 2022. Individuals aged 55 to 80 years with a smoking history of at least 30 pack-years who were current smokers or had quit within the past 15 years were eligible to participate. Individuals with LCS within 15 months were excluded. Of 1047 individuals who were sent a recruitment letter or had referred themselves, 140 were enrolled.Intervention: A web-based patient- and clinician-facing LCS decision support tool vs an attention control intervention.Main Outcome and Measures: The primary outcome was decisional conflict at 1 month. Secondary outcomes included decisional conflict immediately after intervention and 3 months after intervention, knowledge, decisional regret, and anxiety immediately after intervention and 1 and 3 months after intervention and LCS by 6 months.Results: Of 140 enrolled participants (median age, 64.0 [IQR, 61.0-69.0] years), 129 (92.1%) were men and 11 (7.9%) were women. Of 137 participants with data available, 75 (53.6%) were African American or Black and 62 (44.3%) were White; 4 participants (2.9%) also reported Hispanic or Latino ethnicity. Mean decisional conflict score at 1 month did not differ between the LCSDecTool and control groups (25.7 [95% CI, 21.4-30.1] vs 29.9 [95% CI, 25.6-34.2], respectively; P = .18). Mean LCS knowledge score was greater in the LCSDecTool group immediately after intervention (7.0 [95% CI, 6.3-7.7] vs 4.9 [95% CI, 4.3-5.5]; P < .001) and remained higher at 1 month (6.3 [95% CI, 5.7-6.8] vs 5.2 [95% CI, 4.5-5.8]; P = .03) and 3 months (6.2 [95% CI, 5.6-6.8] vs 5.1 [95% CI, 4.4-5.8]; P = .01). Uptake of LCS was greater in the LCSDecTool group at 6 months (26 of 69 [37.7%] vs 15 of 71 [21.1%]; P = .04).Conclusions and Relevance: In this randomized clinical trial of an LCSDecTool compared with attention control, no effect on decisional conflict occurred at 1 month. The LCSDecTool used in the primary care setting did not yield a significant difference in decisional conflict. The intervention led to greater knowledge and LCS uptake. These findings can inform future implementation strategies and research in LCS shared decision-making.Trial Registration: ClinicalTrials.gov Identifier: NCT02899754

17 January 2019 in MDM Policy & Practice
Verified
Journal Article
Open access
PDF file
MSMarilyn M. Schapira
Marilyn M. Schapira
RHRebecca A. Hubbard
Rebecca A. Hubbard
HSHolli H. Seitz
Holli H. Seitz
ECEmily F. Conant
Emily F. Conant
MSMitchell Schnall
Mitchell Schnall
KAKatrina Armstrong
Katrina Armstrong
Background. Guidelines recommend that initiation of breast cancer screening (BCS) among women aged 40 to 49 years include a shared decision-making process. The objective of this study is to evaluate the effect of a breast cancer screening patient decision-aid (BCS-PtDA) on the strength of the relationship between individual risk and the decision to initiate BCS, knowledge, and decisional conflict. Methods. We conducted a randomized clinical trial of a BCS-PtDA that included individual risk estimates compared with usual care. Participants were women 39 to 48 years of age with no previous mammogram. Primary outcomes were strength of association between breast cancer risk and mammography uptake at 12 months, knowledge, and decisional conflict. Results. Of 204 participants, 65% were Black, the median age (interquartile range [IQR]) was 40.0 years (39.0–42.0), and median (IQR) breast cancer lifetime risk was 9.7% (9.2–11.1). Women who received mammography at 12 months had higher breast cancer lifetime risk than women who had not in both intervention (mean, 95% CI): 12.2% (10.8–13.6) versus 10.5% (9.8–11.2), P = 0.04, and control groups: 11.8% (10.4–13.1) versus 9.9% (9.2–10.6), P = 0.02. However, there was no difference between groups in the strength of association between mammography uptake and breast cancer risk (P = 0.87). Follow-up knowledge (0–5) was greater in the intervention versus control group (mean, 95% CI): 3.84 (3.5–4.2) versus 3.17 (2.8–3.5), P = 0.01. There was no change in decisional conflict score (1–100) between the intervention versus control group (mean, 95% CI): 24.8 (19.5–30.2) versus 32.4 (25.9–39.0), P = 0.07. Conclusions. The BCS-PtDA improved knowledge but did not affect risk-based decision making regarding age of initiation of BCS. These findings indicate the complexity of changing behaviors to incorporate objective risk in the medical decision-making process.

1 July 2016 in The Journal of Community and Supportive Oncology
Verified
Journal Article
Open access
SPSteven Palmer
Steven Palmer
ADAngela DeMichele
Angela DeMichele
MSMarilyn Schapira
Marilyn Schapira
Karen GlanzKaren Glanz
Karen Glanz
ABAbigail Blauch
Abigail Blauch
LJLinda Jacobs
Linda Jacobs

26 May 2020 in Cancer
Verified
Journal Article
Open access
PDF file
MSMarilyn M. Schapira
Marilyn M. Schapira
ESEvelyn M. Stevens
Evelyn M. Stevens
JSJames E. Sharpe
James E. Sharpe
LHLauren Hochman
Lauren Hochman
JRJoseph G. Reiter
Joseph G. Reiter
LBLamia P. Barakat
Lamia P. Barakat
Background: Approximately 50% of children with cancer in the United States who are aged <15 years receive primary treatment on a therapeutic clinical trial. To the authors' knowledge, it remains unknown whether trial enrollment has a clinical benefit compared with the best alternative standard therapy and/or off trial (ie, clinical trial effect). The authors conducted a retrospective matched cohort study to compare the morbidity and mortality of pediatric patients with cancer who are treated on a phase 3 clinical trial compared with those receiving standard therapy and/or off trial.Methods: Subjects were aged birth to 19 years; were diagnosed between 2000 and 2010 with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), rhabdomyosarcoma, or neuroblastoma; and had received initial treatment at the Children's Hospital of Philadelphia. On‐trial and off‐trial subjects were matched based on age, race, ethnicity, a diagnosis of Down syndrome (for patients with ALL or AML), prognostic risk level, date of diagnosis, and tumor type.Results: A total of 428 participants were matched in 214 pairs (152 pairs for ALL, 24 pairs for AML, 32 pairs for rhabdomyosarcoma, and 6 pairs for neuroblastoma). The 5‐year survival rate did not differ between those treated on trial versus those treated with standard therapy and/or off trial (86.9% vs 82.2%; P = .093). On‐trial patients had a 32% lower odds of having worse (higher) mortality‐morbidity composite scores, although this did not reach statistical significance (odds ratio, 0.68; 95% confidence interval, 0.45‐1.03 [P = .070]).Conclusions: There was no statistically significant difference in outcomes noted between those patients treated on trial and those treated with standard therapy and/or off trial. However, in partial support of the clinical trial effect, the results of the current study indicate a trend toward more favorable outcomes in children treated on trial compared with those treated with standard therapy and/or off trial. These findings can support decision making regarding enrollment in pediatric phase 3 clinical trials.

9 February 2018 in Academic Radiology
Verified
Journal Article
Closed access
PDF file
MSMarilyn M. Schapira
Marilyn M. Schapira
WBWilliam E. Barlow
William E. Barlow
ECEmily F. Conant
Emily F. Conant
BSBrian L. Sprague
Brian L. Sprague
ATAnna N.A. Tosteson
Anna N.A. Tosteson
BGBerta Geller
Berta Geller